CANTON, Mass. and LAS VEGAS, Oct. 20, 2017 /PRNewswire/ -- For the first time since the recent acquisition of NuTech Medical, Organogenesis Inc. will present its expanded advanced wound care product portfolio at the Symposium on Advanced Wound Care Fall (SAWC Fall) meeting held this week in Las Vegas.
The newly-integrated company, which now offers a portfolio of products for the advanced wound care and surgical and sports medicine markets, will highlight important research and promote updates to its portfolio during SAWC Fall.
Scientific presentations will feature some of the latest developments regarding the continuum of care in wound healing.
"Organogenesis is advancing the standard of care in every phase of the wound healing process," said Gary S. Gillheeney, Sr., President and CEO of Organogenesis. "We've built a comprehensive regenerative medicine portfolio to address wounds of all sizes, helping clinicians to personalize solutions to meet the needs of individual wound care patients. We look forward to demonstrating this to the medical and scientific communities via educational programs and presentations that highlight these advances."
Visitors to the Organogenesis exhibition booth (#321) and attendees of its educational presentations will have the opportunity for a first look at the expanded portfolio, including the newly available 1.6 cm disk size of PuraPly™ Antimicrobial, for biofilm-based wound management of smaller wounds; and Affinity® and NuShield®, two amniotic products recently acquired by Organogenesis. Affinity is the advanced wound care field's only fresh amniotic membrane (not dehydrated; not frozen). As a more complete dehydrated allograft, NuShield is designed to protect and support healing, while providing an easy-to-use, off-the-shelf product available in multiple sizes. Organogenesis' proprietary BioLoc™ process preserves the native amnion and chorion layers in NuShield, with the intermediate (spongy) layer intact.
The Company will also present the latest news and research updates for its flagship bioengineered, FDA-approved living cell-based products, Apligraf® and Dermagraft®.
With more than 1,700 attendees, SAWC Fall is one of the largest wound care meetings of the year and serves as the official meeting site of the Association for the Advancement of Wound Care (AAWC), the nation's largest professional organization dedicated to inter-professional wound healing and tissue preservation.
POSTER PRESENTATIONS OF INTEREST INCLUDE:
Preliminary Evaluation of a Purified Collagen Matrix with Polyhexamethylene Biguanide (PHMB) Antimicrobial Reducing Methicillin Resistant Staphylococcus aureus Infections Using a Porcine Deep Dermal Wound Model
Stephen Davis; Joel Gil; Jose Valdes; Michael Solis; Alexander Higa; Fernando Parajon; Greg Schultz; Jie Li.
A Bioengineered Human Fibroblast-Derived Living Dermal Substitute Shifts Diabetic Fibroblast Phenotype to a Regenerative State in a Three-Dimensional Chronic Wound Tissue Model
Avi Smith; Basil Jones; Jyh-Feei Lin; Ronda Schreiber; Katie Faria; Maya Leschinsky; Olga Kashpur; Jonathan A. Garlick.
Amnion/Chorion Grafts Modulate the Inflammatory Response of Fibroblasts Stimulated with Pro-Inflammatory Cytokines TNF-α and Il-1β
John P. McQuilling; MaryRose Kammer; Kelly Kimmerling; Katie C. Mowry.
Evaluation of Growth Factor Release and Stimulation of Proliferation of Wound Microenvironment Cells with Amnion/Chorion Grafts
John P. McQuilling; Jeremy B. Vines; Katie C. Mowry.
Examining the Use of a Purified Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in the Management of Chronic Wounds
Alisha Oropallo; Krisiva Shyta; Sally Kaplan; Farisha Baksh; Jeffrey Nicastro; Gene Coppa; Russell Caprioli; John Haight; Michael Pliskin; Raymond Ferguson.
Examining the Use of a Purified Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in the Management of Chronic Venous Ulcers
Jon S. Woods; Brian Gillette; Raelina Howell; Michael Acerra; Harold Brem; Scott Gorenstein.
Examining the Use of a Purified Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in the Management of Chronic Pressure Ulcers
Jon S. Woods; Brian Gillette; Raelina Howell; Michael Acerra; Harold Brem; Scott Gorenstein.
Examining the Use of a Purified Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in the Management of Diabetic Foot Ulcers
Jon S. Woods; Brian Gillette; Raelina Howell; Michael Acerra; Harold Brem; Scott Gorenstein.
About Organogenesis
Originally founded as a spin-off from technology developed at MIT, Massachusetts-based Organogenesis Inc. offers a portfolio of regenerative medicine products in advanced wound care and surgical and sports medicine. Organogenesis' versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
Contact:
Angelyn Lowe
(781) 830-2353
alowe@organo.com
SOURCE Organogenesis Inc.